ALL Therapeutics

Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...

What is new in CAR T-cell therapy for ALL?

During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv...

Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL

Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor...

Advances of cell therapies in China: Reducing manufacturing time with FasT dual CAR T-cells

The Multiple Myeloma Hub previously summarised activities on chimeric antigen receptor (CAR) T cells in...

Hyper-CVAD with sequential blinatumomab for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Despite high rates of complete remissions, long-term...

What is new for CAR T-cell therapy for adult patients with ALL?

During the 3rd European CAR T-cell Meeting, the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new...

When should we consider allo-HSCT in a patient with ALL? And when not?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel,...

How should we treat a patient who has a molecular relapse after transplant?

During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford...